Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
70 Years of Levothyroxine / / edited by George J. Kahaly
| 70 Years of Levothyroxine / / edited by George J. Kahaly |
| Autore | Kahaly George J |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Springer Nature, 2021 |
| Descrizione fisica | 1 online resource (XVII, 129 p. 37 illus., 34 illus. in color.) |
| Disciplina |
616.4
615.36 |
| Soggetto topico |
Endocrinology
Pharmacology Pharmacology/Toxicology Hormones tiroides Medicaments Farmacologia Malalties de les glàndules endocrines |
| Soggetto genere / forma | Llibres electrònics |
| Soggetto non controllato |
Endocrinology
Pharmacology/Toxicology Pharmacology Thyroid gland Hypothyroidism TSH Thyroid disorders Metabolism Open Access |
| ISBN | 3-030-63277-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | History Of Levothyroxine -- Pharmacokinetics Of Levothyroxine -- Pharmacodynamics Of Levothyroxine -- Levothyroxine In Pregnancy -- Levothyroxine In Children -- Levothyroxine In The Elderly -- Levothyroxine And Heart -- Levothyroxine And Bone -- Levothyroxine And Cancer -- Potential Adverse Reactions Of Levothyroxine. |
| Record Nr. | UNINA-9910473450103321 |
Kahaly George J
|
||
| Springer Nature, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibody-Drug Conjugates : The 21st Century Magic Bullets for Cancer / / edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro
| Antibody-Drug Conjugates : The 21st Century Magic Bullets for Cancer / / edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro |
| Edizione | [1st ed. 2015.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 |
| Descrizione fisica | 1 online resource (248 p.) |
| Disciplina | 615.36 |
| Collana | AAPS Advances in the Pharmaceutical Sciences Series |
| Soggetto topico |
Pharmaceutical technology
Pharmaceutical Sciences/Technology |
| ISBN | 3-319-13081-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions. |
| Record Nr. | UNINA-9910733727803321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antisense and ribozyme methodology / / Ian Gibson, editor
| Antisense and ribozyme methodology / / Ian Gibson, editor |
| Pubbl/distr/stampa | London, [England] : , : Chapman & Hall, , 1997 |
| Descrizione fisica | 1 online resource (96 p.) |
| Disciplina |
572.88
615.36 |
| Collana | Laboratory Companion Series |
| Soggetto topico |
Antisense nucleic acids
Catalytic RNA |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-84239-7
9786611842390 3-527-61253-X 3-527-61252-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antisense and Ribozyme Methodology; Contents; CHAPTER 1. Antisense and Ribozyme Methodology; 1.1 The Potential; 1.2 Antisense Technology; 1.2.1 Problems; 1.2.2 Resistance to Nucleases; 1.2.3 Entry into Cells; 1.2.4 How Antisense Works; 1.2.5 Success; 1.3 Ribozymes; 1.3.1 What Are They?; 1.3.2 Problems; 1.3.3 Stable Ribozymes; 1.3.4 Designing Ribozymes; 1.4 Ribozymes or Antisense DNAs?; 1.5 The Choice Today!!; CHAPTER 2. Design and Synthesis of Antisense DNA Molecules; 2.1 Introduction; 2.2 Synthesis of Methylphosphonodiester-Phosphodiester Chimeric Oligodeoxynucleotides
2.2.1 Materials and Chemicals2.2.2 Solutions; 2.2.3 Maximizing Product Purity; 2.2.4 Deprotection of Chimeric Oligodeoxynucleotides; 2.2.5 Failed Sequences; 2.3 Primary Purification by Reversed-Phase, Solid-Phase Extraction on C18 SEP-PAK Cartridges; 2.3.1 Equipment; 2.3.2 Method; 2.3.3 Purification of the Oligodeoxynucleotide; 2.3.4 Further Purification; 2.4 Analysis and Purification by HPLC; 2.4.1 Analysis of Chimeric Oligodeoxynucleotides by HPLC; 2.4.2 Purification of Chimeric Oligodeoxynucleotides by HPLC; 2.4.3 Re-Use of Columns 2.5 Synthesis of Chimeric Oligodeoxynucleotides with Fluorescein Attached2.6 Summary; CHAPTER 3. The Design and Synthesis of Hammerhead Ribozymes; 3.1 Introduction; 3.2 The Design of Hammerhead Ribozymes; 3.3 Improving the Reactions; 3.3.1 Accessibility of the Target - Substrate Binding; 3.3.2 Finding the Target; 3.3.3 Theoretical Considerations; 3.3.4 Experimental Approaches; 3.3.5 Kinetic Studies; 3.4 Length of Arms; 3.4.1 Choosing Antisense Arms of Hammerhead Ribozymes; 3.4.2 Arms of Different Lengths; 3.5 Cleavage of the Target Motif; 3.6 Synthesis of Ribozymes 3.6.1 Chemical Synthesis of Short Hammerhead Ribozymes3.6.2 Enzymatic Transcription in Vitro; 3.7 Endogenous Expression of Ribozyme Genes; CHAPTER 4. Delivery of Ribozymes and Antisense DNA Molecules into Mammalian Cells; 4.1 Introduction; 4.2 Exogenous Application; 4.2.1 lntracytoplasmic Delivery of Antisense Oligodeoxynucleotides by Reversible Plasma Membrane Permeabilization with Streptolysin O; 4.3 Microinjection; 4.4 Other Methods Used in Nucleic Acid Transfection; 4.5 Electroporation; 4.5.1 Method; 4.5.2 Transfection: Optimization of Conditions 4.5.3 Mechanism of Uptake Following Electroporation4.5.4 Benefits and Drawbacks of Electrophoretic-Mediated Uptake; 4.6 Diethylaminoethyl-Dextran (DEAE- Dextran) and DNA Transfection; 4.6.1 Methods for Transfection of Adherent Cells; 4.6.2 Possible Alterations of the Above Protocol; 4.6.3 Transfection of Cells Growing in Suspension; 4.6.4 Transfection Optimization; 4.6.5 Distribution Mechanism of DEAE-Dextran Uptake and lntracellular; 4.6.6 Benefits and Drawbacks; 4.7 Calcium Phosphate Transfection; 4.7.1 Method; 4.7.2 Possible Alterations to Above Method; 4.7.3 Method Optimization 4.7.4 Calcium Phosphate-Mediated Uptake and lntracellular Distribution |
| Record Nr. | UNINA-9910144117903321 |
| London, [England] : , : Chapman & Hall, , 1997 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antisense and ribozyme methodology / / Ian Gibson, editor
| Antisense and ribozyme methodology / / Ian Gibson, editor |
| Pubbl/distr/stampa | London, [England] : , : Chapman & Hall, , 1997 |
| Descrizione fisica | 1 online resource (96 p.) |
| Disciplina |
572.88
615.36 |
| Collana | Laboratory Companion Series |
| Soggetto topico |
Antisense nucleic acids
Catalytic RNA |
| ISBN |
1-281-84239-7
9786611842390 3-527-61253-X 3-527-61252-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antisense and Ribozyme Methodology; Contents; CHAPTER 1. Antisense and Ribozyme Methodology; 1.1 The Potential; 1.2 Antisense Technology; 1.2.1 Problems; 1.2.2 Resistance to Nucleases; 1.2.3 Entry into Cells; 1.2.4 How Antisense Works; 1.2.5 Success; 1.3 Ribozymes; 1.3.1 What Are They?; 1.3.2 Problems; 1.3.3 Stable Ribozymes; 1.3.4 Designing Ribozymes; 1.4 Ribozymes or Antisense DNAs?; 1.5 The Choice Today!!; CHAPTER 2. Design and Synthesis of Antisense DNA Molecules; 2.1 Introduction; 2.2 Synthesis of Methylphosphonodiester-Phosphodiester Chimeric Oligodeoxynucleotides
2.2.1 Materials and Chemicals2.2.2 Solutions; 2.2.3 Maximizing Product Purity; 2.2.4 Deprotection of Chimeric Oligodeoxynucleotides; 2.2.5 Failed Sequences; 2.3 Primary Purification by Reversed-Phase, Solid-Phase Extraction on C18 SEP-PAK Cartridges; 2.3.1 Equipment; 2.3.2 Method; 2.3.3 Purification of the Oligodeoxynucleotide; 2.3.4 Further Purification; 2.4 Analysis and Purification by HPLC; 2.4.1 Analysis of Chimeric Oligodeoxynucleotides by HPLC; 2.4.2 Purification of Chimeric Oligodeoxynucleotides by HPLC; 2.4.3 Re-Use of Columns 2.5 Synthesis of Chimeric Oligodeoxynucleotides with Fluorescein Attached2.6 Summary; CHAPTER 3. The Design and Synthesis of Hammerhead Ribozymes; 3.1 Introduction; 3.2 The Design of Hammerhead Ribozymes; 3.3 Improving the Reactions; 3.3.1 Accessibility of the Target - Substrate Binding; 3.3.2 Finding the Target; 3.3.3 Theoretical Considerations; 3.3.4 Experimental Approaches; 3.3.5 Kinetic Studies; 3.4 Length of Arms; 3.4.1 Choosing Antisense Arms of Hammerhead Ribozymes; 3.4.2 Arms of Different Lengths; 3.5 Cleavage of the Target Motif; 3.6 Synthesis of Ribozymes 3.6.1 Chemical Synthesis of Short Hammerhead Ribozymes3.6.2 Enzymatic Transcription in Vitro; 3.7 Endogenous Expression of Ribozyme Genes; CHAPTER 4. Delivery of Ribozymes and Antisense DNA Molecules into Mammalian Cells; 4.1 Introduction; 4.2 Exogenous Application; 4.2.1 lntracytoplasmic Delivery of Antisense Oligodeoxynucleotides by Reversible Plasma Membrane Permeabilization with Streptolysin O; 4.3 Microinjection; 4.4 Other Methods Used in Nucleic Acid Transfection; 4.5 Electroporation; 4.5.1 Method; 4.5.2 Transfection: Optimization of Conditions 4.5.3 Mechanism of Uptake Following Electroporation4.5.4 Benefits and Drawbacks of Electrophoretic-Mediated Uptake; 4.6 Diethylaminoethyl-Dextran (DEAE- Dextran) and DNA Transfection; 4.6.1 Methods for Transfection of Adherent Cells; 4.6.2 Possible Alterations of the Above Protocol; 4.6.3 Transfection of Cells Growing in Suspension; 4.6.4 Transfection Optimization; 4.6.5 Distribution Mechanism of DEAE-Dextran Uptake and lntracellular; 4.6.6 Benefits and Drawbacks; 4.7 Calcium Phosphate Transfection; 4.7.1 Method; 4.7.2 Possible Alterations to Above Method; 4.7.3 Method Optimization 4.7.4 Calcium Phosphate-Mediated Uptake and lntracellular Distribution |
| Record Nr. | UNISA-996203927503316 |
| London, [England] : , : Chapman & Hall, , 1997 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Antisense and ribozyme methodology / / Ian Gibson, editor
| Antisense and ribozyme methodology / / Ian Gibson, editor |
| Pubbl/distr/stampa | London, [England] : , : Chapman & Hall, , 1997 |
| Descrizione fisica | 1 online resource (96 p.) |
| Disciplina |
572.88
615.36 |
| Collana | Laboratory Companion Series |
| Soggetto topico |
Antisense nucleic acids
Catalytic RNA |
| ISBN |
1-281-84239-7
9786611842390 3-527-61253-X 3-527-61252-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antisense and Ribozyme Methodology; Contents; CHAPTER 1. Antisense and Ribozyme Methodology; 1.1 The Potential; 1.2 Antisense Technology; 1.2.1 Problems; 1.2.2 Resistance to Nucleases; 1.2.3 Entry into Cells; 1.2.4 How Antisense Works; 1.2.5 Success; 1.3 Ribozymes; 1.3.1 What Are They?; 1.3.2 Problems; 1.3.3 Stable Ribozymes; 1.3.4 Designing Ribozymes; 1.4 Ribozymes or Antisense DNAs?; 1.5 The Choice Today!!; CHAPTER 2. Design and Synthesis of Antisense DNA Molecules; 2.1 Introduction; 2.2 Synthesis of Methylphosphonodiester-Phosphodiester Chimeric Oligodeoxynucleotides
2.2.1 Materials and Chemicals2.2.2 Solutions; 2.2.3 Maximizing Product Purity; 2.2.4 Deprotection of Chimeric Oligodeoxynucleotides; 2.2.5 Failed Sequences; 2.3 Primary Purification by Reversed-Phase, Solid-Phase Extraction on C18 SEP-PAK Cartridges; 2.3.1 Equipment; 2.3.2 Method; 2.3.3 Purification of the Oligodeoxynucleotide; 2.3.4 Further Purification; 2.4 Analysis and Purification by HPLC; 2.4.1 Analysis of Chimeric Oligodeoxynucleotides by HPLC; 2.4.2 Purification of Chimeric Oligodeoxynucleotides by HPLC; 2.4.3 Re-Use of Columns 2.5 Synthesis of Chimeric Oligodeoxynucleotides with Fluorescein Attached2.6 Summary; CHAPTER 3. The Design and Synthesis of Hammerhead Ribozymes; 3.1 Introduction; 3.2 The Design of Hammerhead Ribozymes; 3.3 Improving the Reactions; 3.3.1 Accessibility of the Target - Substrate Binding; 3.3.2 Finding the Target; 3.3.3 Theoretical Considerations; 3.3.4 Experimental Approaches; 3.3.5 Kinetic Studies; 3.4 Length of Arms; 3.4.1 Choosing Antisense Arms of Hammerhead Ribozymes; 3.4.2 Arms of Different Lengths; 3.5 Cleavage of the Target Motif; 3.6 Synthesis of Ribozymes 3.6.1 Chemical Synthesis of Short Hammerhead Ribozymes3.6.2 Enzymatic Transcription in Vitro; 3.7 Endogenous Expression of Ribozyme Genes; CHAPTER 4. Delivery of Ribozymes and Antisense DNA Molecules into Mammalian Cells; 4.1 Introduction; 4.2 Exogenous Application; 4.2.1 lntracytoplasmic Delivery of Antisense Oligodeoxynucleotides by Reversible Plasma Membrane Permeabilization with Streptolysin O; 4.3 Microinjection; 4.4 Other Methods Used in Nucleic Acid Transfection; 4.5 Electroporation; 4.5.1 Method; 4.5.2 Transfection: Optimization of Conditions 4.5.3 Mechanism of Uptake Following Electroporation4.5.4 Benefits and Drawbacks of Electrophoretic-Mediated Uptake; 4.6 Diethylaminoethyl-Dextran (DEAE- Dextran) and DNA Transfection; 4.6.1 Methods for Transfection of Adherent Cells; 4.6.2 Possible Alterations of the Above Protocol; 4.6.3 Transfection of Cells Growing in Suspension; 4.6.4 Transfection Optimization; 4.6.5 Distribution Mechanism of DEAE-Dextran Uptake and lntracellular; 4.6.6 Benefits and Drawbacks; 4.7 Calcium Phosphate Transfection; 4.7.1 Method; 4.7.2 Possible Alterations to Above Method; 4.7.3 Method Optimization 4.7.4 Calcium Phosphate-Mediated Uptake and lntracellular Distribution |
| Record Nr. | UNINA-9910830630503321 |
| London, [England] : , : Chapman & Hall, , 1997 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Apiterapia : medicamentos das abelhas e possíveis tratamentos / / José Maurício Sforcin
| Apiterapia : medicamentos das abelhas e possíveis tratamentos / / José Maurício Sforcin |
| Autore | Sforcin José Maurício |
| Pubbl/distr/stampa | [Place of publication not identified] : , : Fundação Editora da UNESP, , 2022 |
| Descrizione fisica | 1 online resource (107 pages) |
| Disciplina | 615.36 |
| Soggetto topico |
Bee products - Therapeutic use
Bee products - Health aspects |
| ISBN | 9786557142974 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | por |
| Altri titoli varianti | Apiterapia |
| Record Nr. | UNINA-9910719624103321 |
|
Sforcin José Maurício
|
||
| [Place of publication not identified] : , : Fundação Editora da UNESP, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Approaches to the purifacation, analysis and characterization of antibody-based therapeutics / / edited by Allan Matte [and seven others]
| Approaches to the purifacation, analysis and characterization of antibody-based therapeutics / / edited by Allan Matte [and seven others] |
| Pubbl/distr/stampa | Amsterdam, Netherlands : , : Elsevier Limited, , [2020] |
| Descrizione fisica | 1 online resource (224 pages) |
| Disciplina | 615.36 |
| Soggetto topico |
Antibody-drug conjugates
Immunoglobulins |
| ISBN | 0-08-103019-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Overview of therapeutic antibodies; 2. Platform purification approaches; 3. Strategies in the context of mAb downstream process development; 4. Process-scale purification of antibody therapeutics; 5. Process analytics for mAb purification and process development; 6. Automation approaches for small-scale mAb purification and assay development; 7. Glycan characterization of therapeutics mAbs; 8. Characterization of therapeutic antibodies using mass spectrometry; 9. Antibody binding studies using surface plasmon resonance and bio-layer interferometry methods; 10. Higher-order structure characterization methods; 11. Conformational and colloidal stability analysis of mAbs; 12. Future trends and opportunities. |
| Record Nr. | UNINA-9910583324403321 |
| Amsterdam, Netherlands : , : Elsevier Limited, , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Garum and Salsamenta : Production and commerce in Materia Medica / by Robert I. Curtis
| Garum and Salsamenta : Production and commerce in Materia Medica / by Robert I. Curtis |
| Autore | CURTIS, Robert I. |
| Pubbl/distr/stampa | Leiden, : Brill, 1999 |
| Descrizione fisica | xv, 8 p. di tav., 226 p. ; 25 cm |
| Disciplina | 615.36(MATERIA MEDICA - FARMACI DI ORIGINE ANIMALE) |
| Soggetto topico |
MEDICINA - Roma antica
PESCE SALATO - Uso terapeutico - Storia PESCE - Commercio - Impero romano |
| ISBN | 90-04-09423-7 |
| Classificazione | Q5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNIOR-UON00095153 |
|
CURTIS, Robert I.
|
||
| Leiden, : Brill, 1999 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. L'Orientale | ||
| ||
Impiego del propoli in agricoltura / [F.Garofalo, L. Pecchiai]
| Impiego del propoli in agricoltura / [F.Garofalo, L. Pecchiai] |
| Pubbl/distr/stampa | [Torino] : Associazione Suolo e salute, 1988 printing |
| Descrizione fisica | 1 volume (unpaged) : ill. ; 22 cm |
| Disciplina | 615.36 |
| Altri autori (Persone) |
Garofalo, Francesco
Pecchiai, Luciano |
| Soggetto topico | Propolis |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | ita |
| Record Nr. | UNISALENTO-991004360035407536 |
| [Torino] : Associazione Suolo e salute, 1988 printing | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. del Salento | ||
| ||
Journal of clinical endocrinology and metabolism
| Journal of clinical endocrinology and metabolism |
| Pubbl/distr/stampa | Springfield, : Issued for the Endocrine Society by the Williams & Wilkins Co. |
| Disciplina |
616
615.36 |
| ISSN | 0021-972X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990008987060403321 |
| Springfield, : Issued for the Endocrine Society by the Williams & Wilkins Co. | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
